Phase 1 (Data / Information)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Galidesivir (BCX4430) - Phase 1 (Data / Information)
ClinicalTrial.gov (NCT03891420): A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19
WHAT IS THE CATALYST EVENT?
Phase 1 Data / Information (slides 6, 14)
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
posters and publications
MECHANISM OF ACTION / RATIONALE
Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. In vitro, it displayed broad-spectrum antiviral activity against various negative- and positive-sense RNA viruses, including coronaviruses, filoviruses, and arenaviruses. Phase 1 clinical trials have begun to determine the safety of this drug in humans. Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19 (Learn more - National Library of Medicine)
Updated by HC
#BCRX, #Galidesivir, #BCX4430, #COVID
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post